Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 6/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16834258 | 0.82 | ALDH1A1 (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL20055871 | 0.82 | ALDH1A1 (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31480075 | 0.79 | TTR (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL20031456 | 0.78 | KDM4E (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2638000 | 0.77 | HTR3A (0.58) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL9005458 | 0.77 | PRKCQ (0.62) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL3466851 | 0.76 | CNR1 (0.48) | TSHR | |
| Hydrochloric Acid SCHEMBL3466386 | 0.76 | HTR3A (0.57) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31469904 | 0.75 | ALOX5 (0.47) | SORDGRM1 | |
| SCHEMBL31383621 | 0.75 | ALOX5 (0.47) | SORDGRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | KDM4E 2255/4885ALOX15 660/4885TSHR 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.